Alkermes PLC (NASDAQ:ALKS) will post its quarterly earnings results before the market opens on Thursday, October 26th. Analysts expect Alkermes PLC to post earnings of $0.01 per share for the quarter.

Alkermes PLC (NASDAQ:ALKS) last posted its quarterly earnings data on Thursday, July 27th. The company reported $0.01 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.01) by $0.02. Alkermes PLC had a negative return on equity of 9.12% and a negative net margin of 24.33%. The company had revenue of $218.80 million during the quarter, compared to analyst estimates of $216.54 million. During the same quarter last year, the company earned ($0.01) EPS. The firm’s revenue for the quarter was up 12.1% on a year-over-year basis. On average, analysts expect Alkermes PLC to post $-0.68 EPS for the current fiscal year and $-0.39 EPS for the next fiscal year.

Alkermes PLC (NASDAQ:ALKS) traded down 0.22% on Friday, reaching $50.45. The company had a trading volume of 25,420 shares. The stock’s 50-day moving average is $51.19 and its 200-day moving average is $55.33. The company’s market capitalization is $7.75 billion. Alkermes PLC has a 52 week low of $48.90 and a 52 week high of $63.40.

In other Alkermes PLC news, CAO Kathryn L. Biberstein sold 13,566 shares of the stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $51.29, for a total value of $695,800.14. Following the completion of the sale, the chief accounting officer now owns 70,455 shares in the company, valued at approximately $3,613,636.95. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Paul J. Mitchell sold 1,500 shares of the stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $54.91, for a total transaction of $82,365.00. Following the completion of the sale, the director now owns 9,500 shares of the company’s stock, valued at approximately $521,645. The disclosure for this sale can be found here. Insiders sold a total of 18,066 shares of company stock worth $930,280 over the last ninety days. 5.34% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: “Alkermes PLC (ALKS) to Release Quarterly Earnings on Thursday” was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US and international copyright and trademark laws. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/20/alkermes-plc-alks-to-release-quarterly-earnings-on-thursday.html.

ALKS has been the topic of a number of recent analyst reports. ValuEngine downgraded Alkermes PLC from a “hold” rating to a “sell” rating in a research report on Thursday, July 27th. Zacks Investment Research raised Alkermes PLC from a “sell” rating to a “hold” rating in a research report on Wednesday, August 2nd. BidaskClub downgraded Alkermes PLC from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. Jefferies Group LLC set a $69.00 target price on Alkermes PLC and gave the company a “buy” rating in a research report on Friday, August 25th. Finally, Barclays PLC downgraded Alkermes PLC from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $66.00 to $50.00 in a research report on Monday. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the company. Alkermes PLC has an average rating of “Hold” and a consensus price target of $62.56.

Alkermes PLC Company Profile

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Earnings History for Alkermes PLC (NASDAQ:ALKS)

Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with MarketBeat.com's FREE daily email newsletter.